Logo image of XXII

22ND CENTURY GROUP INC (XXII) Stock Fundamental Analysis

USA - NASDAQ:XXII - US90137F5098 - Common Stock

1.52 USD
-0.04 (-2.56%)
Last: 10/10/2025, 9:04:10 PM
1.49 USD
-0.03 (-1.97%)
After Hours: 10/10/2025, 9:04:10 PM
Fundamental Rating

3

Overall XXII gets a fundamental rating of 3 out of 10. We evaluated XXII against 8 industry peers in the Tobacco industry. The financial health of XXII is average, but there are quite some concerns on its profitability. XXII has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

XXII had negative earnings in the past year.
XXII had a negative operating cash flow in the past year.
In the past 5 years XXII always reported negative net income.
In the past 5 years XXII always reported negative operating cash flow.
XXII Yearly Net Income VS EBIT VS OCF VS FCFXXII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

XXII has a worse Return On Assets (-99.71%) than 87.50% of its industry peers.
XXII's Return On Equity of -396.39% is in line compared to the rest of the industry. XXII outperforms 50.00% of its industry peers.
Industry RankSector Rank
ROA -99.71%
ROE -396.39%
ROIC N/A
ROA(3y)-239.28%
ROA(5y)-159.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XXII Yearly ROA, ROE, ROICXXII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

XXII does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XXII Yearly Profit, Operating, Gross MarginsXXII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

XXII does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XXII has been increased compared to 1 year ago.
Compared to 5 years ago, XXII has more shares outstanding
The debt/assets ratio for XXII has been reduced compared to a year ago.
XXII Yearly Shares OutstandingXXII Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
XXII Yearly Total Debt VS Total AssetsXXII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -26.13, we must say that XXII is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of XXII (-26.13) is worse than 62.50% of its industry peers.
XXII has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -26.13
ROIC/WACCN/A
WACC8.04%
XXII Yearly LT Debt VS Equity VS FCFXXII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 0.77 indicates that XXII may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.77, XXII is doing worse than 75.00% of the companies in the same industry.
XXII has a Quick Ratio of 0.77. This is a bad value and indicates that XXII is not financially healthy enough and could expect problems in meeting its short term obligations.
XXII has a Quick ratio of 0.61. This is in the lower half of the industry: XXII underperforms 62.50% of its industry peers.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.61
XXII Yearly Current Assets VS Current LiabilitesXXII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

XXII shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.90%, which is quite impressive.
Looking at the last year, XXII shows a very negative growth in Revenue. The Revenue has decreased by -32.51% in the last year.
XXII shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.15% yearly.
EPS 1Y (TTM)98.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3680.56%
Revenue 1Y (TTM)-32.51%
Revenue growth 3Y-7.64%
Revenue growth 5Y-1.15%
Sales Q2Q%-48.64%

3.2 Future

The Earnings Per Share is expected to grow by 41.72% on average over the next years. This is a very strong growth
Based on estimates for the next years, XXII will show a quite strong growth in Revenue. The Revenue will grow by 12.98% on average per year.
EPS Next Y93.77%
EPS Next 2Y41.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-43.66%
Revenue Next 2Y12.98%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XXII Yearly Revenue VS EstimatesXXII Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
XXII Yearly EPS VS EstimatesXXII Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 0 -100K -200K -300K

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

XXII reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 8.77, the valuation of XXII can be described as reasonable.
Based on the Price/Forward Earnings ratio, XXII is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
XXII is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.57, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 8.77
XXII Price Earnings VS Forward Price EarningsXXII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XXII Per share dataXXII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -500 -1K -1.5K -2K

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
XXII's earnings are expected to grow with 41.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.72%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XXII!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

22ND CENTURY GROUP INC

NASDAQ:XXII (10/10/2025, 9:04:10 PM)

After market: 1.49 -0.03 (-1.97%)

1.52

-0.04 (-2.56%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryTobacco
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners0.88%
Inst Owner Change0%
Ins Owners1.91%
Ins Owner Change0%
Market Cap5.75M
Analysts82.86
Price Target5.1 (235.53%)
Short Float %2.67%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-148.29%
Min EPS beat(2)-181.72%
Max EPS beat(2)-114.86%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.09%
Min Revenue beat(2)-26.42%
Max Revenue beat(2)24.24%
Revenue beat(4)1
Avg Revenue beat(4)-22.45%
Min Revenue beat(4)-55.74%
Max Revenue beat(4)24.24%
Revenue beat(8)1
Avg Revenue beat(8)-24.92%
Revenue beat(12)2
Avg Revenue beat(12)-26.25%
Revenue beat(16)3
Avg Revenue beat(16)-19.83%
PT rev (1m)0%
PT rev (3m)-58.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)75.59%
EPS NY rev (1m)93.43%
EPS NY rev (3m)93.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-49.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-35.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.77
P/S 0.29
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2190.45
EYN/A
EPS(NY)0.17
Fwd EY11.41%
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-3.66
OCFYN/A
SpS5.29
BVpS1.49
TBVpS-0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.71%
ROE -396.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-239.28%
ROA(5y)-159.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.83%
Cap/Sales 0.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.61
Altman-Z -26.13
F-Score4
WACC8.04%
ROIC/WACCN/A
Cap/Depr(3y)104.4%
Cap/Depr(5y)87.56%
Cap/Sales(3y)9.68%
Cap/Sales(5y)6.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3680.56%
EPS Next Y93.77%
EPS Next 2Y41.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-32.51%
Revenue growth 3Y-7.64%
Revenue growth 5Y-1.15%
Sales Q2Q%-48.64%
Revenue Next Year-43.66%
Revenue Next 2Y12.98%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.64%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.04%
OCF growth 3YN/A
OCF growth 5YN/A